老虎证券

BRIEF-MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demonstrating Its Best-In-Class Potential

Reuters
04/22
BRIEF-MetaVia Reports Additional Positive Top-Line Results From The Mad Part 2 Of Its Phase 1 Study Of Da-1726, A Novel 31 Ratio Glp-1 And Glucagon Dual Receptor Agonist To Treat Obesity, Further Demonstrating Its Best-In-Class Potential

April 22 (Reuters) - MetaVia Inc MTVA.O:

  • METAVIA REPORTS ADDITIONAL POSITIVE TOP-LINE RESULTS FROM THE MAD PART 2 OF ITS PHASE 1 STUDY OF DA-1726, A NOVEL 3:1 RATIO GLP-1 AND GLUCAGON DUAL RECEPTOR AGONIST TO TREAT OBESITY, FURTHER DEMONSTRATING ITS BEST-IN-CLASS POTENTIAL

  • METAVIA INC: A DOSE-DEPENDENT RESPONSE IN BODY WEIGHT REDUCTION WAS OBSERVED BETWEEN 8 MG AND 32 MG DOSES

  • METAVIA INC: CHANGE IN BMI AND BODY WEIGHT ADJUSTED FOR HEIGHT IN TREATMENT GROUPS, SHOWED A SIGNIFICANT DIFFERENCE COMPARED TO PLACEBO

  • METAVIA: NO DRUG-INDUCED CARDIOVASCULAR EFFECTS OBSERVED IN HEART RATE/QTCF MEASUREMENTS OF SUBJECTS GETTING UP TO 32 MG OF DA-1726 AT 4-WEEKS

  • METAVIA INC: ADDITIONAL COHORTS BEING ADDED TO DETERMINE MAXIMUM TOLERATED DOSE

Source text: ID:nPn48yhCwa

Further company coverage: MTVA.O

((Reuters.Briefs@thomsonreuters.com;))

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10